203 related articles for article (PubMed ID: 23127989)
1. Discovery of new scaffolds for rational design of HCV NS5B polymerase inhibitors.
Golub AG; Gurukumar KR; Basu A; Bdzhola VG; Bilokin Y; Yarmoluk SM; Lee JC; Talele TT; Nichols DB; Kaushik-Basu N
Eur J Med Chem; 2012 Dec; 58():258-64. PubMed ID: 23127989
[TBL] [Abstract][Full Text] [Related]
2. Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase.
Talele TT; Arora P; Kulkarni SS; Patel MR; Singh S; Chudayeu M; Kaushik-Basu N
Bioorg Med Chem; 2010 Jul; 18(13):4630-8. PubMed ID: 20627595
[TBL] [Abstract][Full Text] [Related]
3. 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.
Küçükgüzel I; Satılmış G; Gurukumar KR; Basu A; Tatar E; Nichols DB; Talele TT; Kaushik-Basu N
Eur J Med Chem; 2013 Nov; 69():931-41. PubMed ID: 24161679
[TBL] [Abstract][Full Text] [Related]
4. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors.
Musmuca I; Caroli A; Mai A; Kaushik-Basu N; Arora P; Ragno R
J Chem Inf Model; 2010 Apr; 50(4):662-76. PubMed ID: 20225870
[TBL] [Abstract][Full Text] [Related]
5. Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors.
Therese PJ; Manvar D; Kondepudi S; Battu MB; Sriram D; Basu A; Yogeeswari P; Kaushik-Basu N
J Chem Inf Model; 2014 Feb; 54(2):539-52. PubMed ID: 24460140
[TBL] [Abstract][Full Text] [Related]
6. Discovery and initial optimization of alkoxyanthranilic acid derivatives as inhibitors of HCV NS5B polymerase.
Parcella K; Nickel A; Beno BR; Sheriff S; Wan C; Wang YK; Roberts SB; Meanwell NA; Kadow JF
Bioorg Med Chem Lett; 2017 Jan; 27(2):295-298. PubMed ID: 27908764
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking.
Wei Y; Li J; Qing J; Huang M; Wu M; Gao F; Li D; Hong Z; Kong L; Huang W; Lin J
PLoS One; 2016; 11(2):e0148181. PubMed ID: 26845440
[TBL] [Abstract][Full Text] [Related]
8. Discovery of N-arylalkyl-3-hydroxy-4-oxo-3,4-dihydroquinazolin-2-carboxamide derivatives as HCV NS5B polymerase inhibitors.
Deore RR; Chen GS; Chang PT; Chern TR; Lai SY; Chuang MH; Lin JH; Kung FL; Chen CS; Chiou CT; Chern JW
ChemMedChem; 2012 May; 7(5):850-60. PubMed ID: 22383290
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L
Bioorg Med Chem Lett; 2018 Mar; 28(5):963-968. PubMed ID: 29422387
[TBL] [Abstract][Full Text] [Related]
10. Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors.
May MM; Brohm D; Harrenga A; Marquardt T; Riedl B; Kreuter J; Zimmermann H; Ruebsamen-Schaeff H; Urban A
Antiviral Res; 2012 Aug; 95(2):182-91. PubMed ID: 22580131
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel HCV polymerase inhibitors using pharmacophore-based virtual screening.
Kim ND; Chun H; Park SJ; Yang JW; Kim JW; Ahn SK
Bioorg Med Chem Lett; 2011 Jun; 21(11):3329-34. PubMed ID: 21531135
[TBL] [Abstract][Full Text] [Related]
12. I. Novel HCV NS5B polymerase inhibitors: discovery of indole 2-carboxylic acids with C3-heterocycles.
Anilkumar GN; Lesburg CA; Selyutin O; Rosenblum SB; Zeng Q; Jiang Y; Chan TY; Pu H; Vaccaro H; Wang L; Bennett F; Chen KX; Duca J; Gavalas S; Huang Y; Pinto P; Sannigrahi M; Velazquez F; Venkatraman S; Vibulbhan B; Agrawal S; Butkiewicz N; Feld B; Ferrari E; He Z; Jiang CK; Palermo RE; McMonagle P; Huang HC; Shih NY; Njoroge G; Kozlowski JA
Bioorg Med Chem Lett; 2011 Sep; 21(18):5336-41. PubMed ID: 21840715
[TBL] [Abstract][Full Text] [Related]
13. Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics.
Zhang HX; Li Y; Wang X; Xiao ZT; Wang YH
Curr Med Chem; 2011; 18(26):4019-28. PubMed ID: 21824089
[TBL] [Abstract][Full Text] [Related]
14. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition.
Biswal BK; Wang M; Cherney MM; Chan L; Yannopoulos CG; Bilimoria D; Bedard J; James MN
J Mol Biol; 2006 Aug; 361(1):33-45. PubMed ID: 16828488
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of coumarin and neoflavone derivatives as HCV NS5B polymerase inhibitors.
Nichols DB; Leão RA; Basu A; Chudayeu M; de Moraes Pde F; Talele TT; Costa PR; Kaushik-Basu N
Chem Biol Drug Des; 2013 May; 81(5):607-14. PubMed ID: 23311976
[TBL] [Abstract][Full Text] [Related]
16. Identification of allosteric inhibitors blocking the hepatitis C virus polymerase NS5B in the RNA synthesis initiation step.
Betzi S; Eydoux C; Bussetta C; Blemont M; Leyssen P; Debarnot C; Ben-Rahou M; Haiech J; Hibert M; Gueritte F; Grierson DS; Romette JL; Guillemot JC; Neyts J; Alvarez K; Morelli X; Dutartre H; Canard B
Antiviral Res; 2009 Oct; 84(1):48-59. PubMed ID: 19589358
[TBL] [Abstract][Full Text] [Related]
17. Novel 4-thiazolidinones as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase.
Çakir G; Küçükgüzel İ; Guhamazumder R; Tatar E; Manvar D; Basu A; Patel BA; Zia J; Talele TT; Kaushik-Basu N
Arch Pharm (Weinheim); 2015 Jan; 348(1):10-22. PubMed ID: 25449674
[TBL] [Abstract][Full Text] [Related]
18. Structural and regulatory elements of HCV NS5B polymerase--β-loop and C-terminal tail--are required for activity of allosteric thumb site II inhibitors.
Boyce SE; Tirunagari N; Niedziela-Majka A; Perry J; Wong M; Kan E; Lagpacan L; Barauskas O; Hung M; Fenaux M; Appleby T; Watkins WJ; Schmitz U; Sakowicz R
PLoS One; 2014; 9(1):e84808. PubMed ID: 24416288
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype.
Beaulieu PL; Coulombe R; Duan J; Fazal G; Godbout C; Hucke O; Jakalian A; Joly MA; Lepage O; Llinàs-Brunet M; Naud J; Poirier M; Rioux N; Thavonekham B; Kukolj G; Stammers TA
Bioorg Med Chem Lett; 2013 Jul; 23(14):4132-40. PubMed ID: 23768906
[TBL] [Abstract][Full Text] [Related]
20. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.
Hang JQ; Yang Y; Harris SF; Leveque V; Whittington HJ; Rajyaguru S; Ao-Ieong G; McCown MF; Wong A; Giannetti AM; Le Pogam S; Talamás F; Cammack N; Nájera I; Klumpp K
J Biol Chem; 2009 Jun; 284(23):15517-29. PubMed ID: 19246450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
